Skip to main content
Erschienen in: Surgical Endoscopy 4/2017

23.08.2016

Barrett’s esophagus after Roux-en-Y gastric bypass: does regression occur?

verfasst von: Verónica Gorodner, Rudolf Buxhoeveden, Gastón Clemente, Christian Sánchez, Luis Caro, Alejandro Grigaites

Erschienen in: Surgical Endoscopy | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Barrett’s esophagus (BE) is recognized as a premalignant lesion for esophageal adenocarcinoma. BE appears as a consequence of gastroesophageal reflux disease (GERD), which is increased among obese population. Laparoscopic Roux-en-Y gastric bypass (LRYGB) is the best treatment option for obesity combined with GERD. However, data on evolution of BE after LRYGB are scarce.

Methods and procedures

Patients were studied with esophagogastroduodenoscopy (EGD) and gastric biopsy preoperatively. If BE was suspected, esophageal biopsy was performed. If BE was confirmed, LRYGB was indicated with yearly surveillance EGD with biopsies. LRYGB patients who had BE with at least 1-year follow-up were included.

Results

Between 10/07 and 1/16, 2144 patients underwent laparoscopic bariatric surgery at our institution. There were 1681 (78 %) LRYGB, 399 (19 %) laparoscopic sleeve gastrectomies, and 64 (3 %) revisions. Nineteen patients (0.9 %) had BE preoperatively, and they all underwent LRYGB; 11 of them (58 %) were eligible for this study. There were 6 women and 5 men, mean age 49 ± 11 years, initial BMI 44 ± 6 kg/m2. Mean follow-up was 41 ± 31 months; there were 9 short-segment BE (SSBE) and 2 long-segment BE (LSBE). On pre- and post-op EGD, BE length was 2.1 ± 1.6 and 1.2 ± 1.2 cm, respectively (p = NS). Post-op EGD was compatible with BE in all cases, although esophageal biopsy showed remission in 4 (36 %) cases: three short-segment BE (SSBE) and one long-segment BE (LSBE). One patient was indefinite for dysplasia and remained the same after the operation.

Conclusion

Our preliminary data showed that LRYGB is a suitable treatment option for obese patients with BE, demonstrated by 36 % regression rate of this premalignant disease. Although BE persisted in the remaining patients, no progression to dysplasia was observed. A larger number of patients and longer follow-up are needed for more definitive conclusions.
Literatur
1.
Zurück zum Zitat Braghetto I, Korn O, Csendes A, Gutiérrez L, Valladares H, Chacon M (2012) Laparoscopic treatment of obese patients with gastroesophageal reflux disease and barrett’s esophagus: a prospective study. Obes Surg 22(5):764–772CrossRefPubMed Braghetto I, Korn O, Csendes A, Gutiérrez L, Valladares H, Chacon M (2012) Laparoscopic treatment of obese patients with gastroesophageal reflux disease and barrett’s esophagus: a prospective study. Obes Surg 22(5):764–772CrossRefPubMed
2.
Zurück zum Zitat Akiyamaa T, Yonedab M, Maedab S, Nakajimab A, Koyamaa S, Inamor M (2011) Visceral obesity and the risk of Barrett’s Esophagus. Digestion 83:142–145CrossRef Akiyamaa T, Yonedab M, Maedab S, Nakajimab A, Koyamaa S, Inamor M (2011) Visceral obesity and the risk of Barrett’s Esophagus. Digestion 83:142–145CrossRef
3.
Zurück zum Zitat Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL (2007) Central adiposity and risk of Barrett’s esophagus. Gastroenterology 133(2):403–411CrossRefPubMed Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL (2007) Central adiposity and risk of Barrett’s esophagus. Gastroenterology 133(2):403–411CrossRefPubMed
4.
Zurück zum Zitat Oelschlager BK, Barreca M, Chang L, Oleynikov D, Pellegrini CA (2003) Clinical and pathologic response of Barrett’s esophagus to laparoscopic antireflux surgery. Ann Surg 238(4):458–464 (discussion 464–466) PubMedPubMedCentral Oelschlager BK, Barreca M, Chang L, Oleynikov D, Pellegrini CA (2003) Clinical and pathologic response of Barrett’s esophagus to laparoscopic antireflux surgery. Ann Surg 238(4):458–464 (discussion 464–466) PubMedPubMedCentral
5.
Zurück zum Zitat Madalosso CA, Gurski RR, Callegari-Jacques SM, Navarini D, Thiesen V, Fornari F (2010) The impact of gastric bypass on gastroesophageal reflux disease in patients with morbid obesity: a prospective study based on the montreal consensus. Ann Surg 251:244–248CrossRefPubMed Madalosso CA, Gurski RR, Callegari-Jacques SM, Navarini D, Thiesen V, Fornari F (2010) The impact of gastric bypass on gastroesophageal reflux disease in patients with morbid obesity: a prospective study based on the montreal consensus. Ann Surg 251:244–248CrossRefPubMed
6.
Zurück zum Zitat Nelson LG, Gonzalez R, Haines K, Gallagher SF, Murr MM (2005) Amelioration of gastroesophageal reflux symptoms following Roux-en-Y gastric bypass for clinically significant obesity. Am Surg 71:950–953 (discussion 953–954) PubMed Nelson LG, Gonzalez R, Haines K, Gallagher SF, Murr MM (2005) Amelioration of gastroesophageal reflux symptoms following Roux-en-Y gastric bypass for clinically significant obesity. Am Surg 71:950–953 (discussion 953–954) PubMed
7.
Zurück zum Zitat Gastrointestinal Surgery for Obesity (1992) National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 55:615S–619S Gastrointestinal Surgery for Obesity (1992) National Institutes of Health Consensus Development Conference Statement. Am J Clin Nutr 55:615S–619S
8.
Zurück zum Zitat Lundell LR, Dent J, Bennett JR, Blum AL, Amstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GNJ, Wallin L (1999) Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of Los Angeles classification. Gut 45(2):172–180CrossRefPubMedPubMedCentral Lundell LR, Dent J, Bennett JR, Blum AL, Amstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GNJ, Wallin L (1999) Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of Los Angeles classification. Gut 45(2):172–180CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Houghton SG, Romero Y, Sarr MG (2008) Effect of Roux-en-Y gastric bypass in obese patients with Barrett’s esophagus: attempts to eliminate duodenogastric reflux. Surg Obes Relat Dis 4:1–5CrossRefPubMed Houghton SG, Romero Y, Sarr MG (2008) Effect of Roux-en-Y gastric bypass in obese patients with Barrett’s esophagus: attempts to eliminate duodenogastric reflux. Surg Obes Relat Dis 4:1–5CrossRefPubMed
10.
Zurück zum Zitat Cobey F, Oelschlager B (2005) Complete regression of Barrett’s esophagus after Roux-en-Y gastric bypass. Obes Surg 15(5):710–712CrossRefPubMed Cobey F, Oelschlager B (2005) Complete regression of Barrett’s esophagus after Roux-en-Y gastric bypass. Obes Surg 15(5):710–712CrossRefPubMed
11.
Zurück zum Zitat Gurski R, Peters JH, Hagen JA, DeMeester SR, Bremner CD, Chandrasoma PT, DeMeester TR (2003) Barrett’s esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg 196(5):706–712 (discussion 712–713) CrossRef Gurski R, Peters JH, Hagen JA, DeMeester SR, Bremner CD, Chandrasoma PT, DeMeester TR (2003) Barrett’s esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg 196(5):706–712 (discussion 712–713) CrossRef
12.
Zurück zum Zitat Morrow E, Bushyhead D, Wassenaar E, Hinojosa E, Loviscek M, Pellegrini C, Oelschlager B (2014) The impact of laparoscopic anti-reflux surgery in patients with Barrett’s esophagus. Surg Endosc 28:3279–3284CrossRefPubMed Morrow E, Bushyhead D, Wassenaar E, Hinojosa E, Loviscek M, Pellegrini C, Oelschlager B (2014) The impact of laparoscopic anti-reflux surgery in patients with Barrett’s esophagus. Surg Endosc 28:3279–3284CrossRefPubMed
13.
Zurück zum Zitat Perez AR, Moncure AC, Rattner DW (2001) Obesity adversely affects the outcome of antireflux operations. Surg Endosc 15(9):986–989CrossRefPubMed Perez AR, Moncure AC, Rattner DW (2001) Obesity adversely affects the outcome of antireflux operations. Surg Endosc 15(9):986–989CrossRefPubMed
14.
Zurück zum Zitat Mejía-Rivas MA, Herrera-López A, Hernández-Calleros J, Herrera MF, Valdovinos MA (2008) Gastroesophageal reflux disease in morbid obesity: the effect of Roux-en-Y gastric bypass. Obes Surg 18:1217–1224CrossRefPubMed Mejía-Rivas MA, Herrera-López A, Hernández-Calleros J, Herrera MF, Valdovinos MA (2008) Gastroesophageal reflux disease in morbid obesity: the effect of Roux-en-Y gastric bypass. Obes Surg 18:1217–1224CrossRefPubMed
15.
Zurück zum Zitat Grigaites A, Buxhoeveden RB, Helman B, Gorodner V, Carrillo F, Marcolini A, Awruch D (2014) Postoperative morbidity and mortality in laparoscopic bariatric surgery: experience in 1020 patients. Rev Argent Cirug 106(2):103–109 Grigaites A, Buxhoeveden RB, Helman B, Gorodner V, Carrillo F, Marcolini A, Awruch D (2014) Postoperative morbidity and mortality in laparoscopic bariatric surgery: experience in 1020 patients. Rev Argent Cirug 106(2):103–109
16.
Zurück zum Zitat Rossidis G, Browning R, Hochwald S, Abbas H, Kim T, Ben-David K (2014) Minimally invasive esophagectomy is safe in patients with previous gastric bypass. Surg Obes Relat Dis 10(1):95–100CrossRefPubMed Rossidis G, Browning R, Hochwald S, Abbas H, Kim T, Ben-David K (2014) Minimally invasive esophagectomy is safe in patients with previous gastric bypass. Surg Obes Relat Dis 10(1):95–100CrossRefPubMed
17.
Zurück zum Zitat Kuruba R, Jawad M, Karl RC, Murr MM (2009) Technique of resection of esophageal adenocarcinoma after Roux-en-Y gastric bypass and literature review of esophagogastric tumors after bariatric procedures. Surg Obes Relat Dis 5(5):576–581CrossRefPubMed Kuruba R, Jawad M, Karl RC, Murr MM (2009) Technique of resection of esophageal adenocarcinoma after Roux-en-Y gastric bypass and literature review of esophagogastric tumors after bariatric procedures. Surg Obes Relat Dis 5(5):576–581CrossRefPubMed
18.
Zurück zum Zitat Nguyen NT, Tran CL, Gelfand DV, Varela E, Chang K, Stamis M, Wilson SE (2006) Laparoscopic and thoracoscopic Ivor Lewis esophagectomy after Roux-en-Y gastric bypass. Ann Thorac Surg 82(5):1910–1913CrossRefPubMed Nguyen NT, Tran CL, Gelfand DV, Varela E, Chang K, Stamis M, Wilson SE (2006) Laparoscopic and thoracoscopic Ivor Lewis esophagectomy after Roux-en-Y gastric bypass. Ann Thorac Surg 82(5):1910–1913CrossRefPubMed
Metadaten
Titel
Barrett’s esophagus after Roux-en-Y gastric bypass: does regression occur?
verfasst von
Verónica Gorodner
Rudolf Buxhoeveden
Gastón Clemente
Christian Sánchez
Luis Caro
Alejandro Grigaites
Publikationsdatum
23.08.2016
Verlag
Springer US
Erschienen in
Surgical Endoscopy / Ausgabe 4/2017
Print ISSN: 0930-2794
Elektronische ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-016-5184-3

Weitere Artikel der Ausgabe 4/2017

Surgical Endoscopy 4/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.